In this EASL Studio Podcast, a very special interview with Prof. Stephan Urban talking about his journey of the discovery and development of the first HBV/HDV entry inhibitor.

• Where did the story begin and what were the major breakthroughs and challenges?
• What are the mechanisms of viral entry inhibitors and how it differs from direct acting antivirals mode of action?
• How does it impact the future of HBV/HDV treatment landscape?

This project has been made possible with the provision of a financial grant from Gilead Sciences Europe Ltd.
EASL has received no input from Gilead with regard to the content of this programme.

Read more: https://easlcampus.eu/podcasts/easl-studio-podcast-s2e3-interview-stephan-urban-bench-bedside-process-developing-first